TJ347B - Cryptophicin compounds pharmacentical composition method to inhibit the proliteration of cells and and method to treat neoplasia - Google Patents

Cryptophicin compounds pharmacentical composition method to inhibit the proliteration of cells and and method to treat neoplasia

Info

Publication number
TJ347B
TJ347B TJ97000493A TJ97000493A TJ347B TJ 347 B TJ347 B TJ 347B TJ 97000493 A TJ97000493 A TJ 97000493A TJ 97000493 A TJ97000493 A TJ 97000493A TJ 347 B TJ347 B TJ 347B
Authority
TJ
Tajikistan
Prior art keywords
proliteration
cryptophicin
inhibit
cells
compounds
Prior art date
Application number
TJ97000493A
Other languages
English (en)
Inventor
Richard E Moore
Marcus A Tius
Russell A Barrow
Jian Liang
Thomas H Corbert
Fredrick A Valeriot
Thomas K Hemscheidt
Original Assignee
Univ Hawaii
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/400,057 external-priority patent/US6013626A/en
Priority claimed from US08/482,141 external-priority patent/US5952298A/en
Application filed by Univ Hawaii, Univ Wayne State filed Critical Univ Hawaii
Publication of TJ347B publication Critical patent/TJ347B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TJ97000493A 1995-03-07 1996-03-07 Cryptophicin compounds pharmacentical composition method to inhibit the proliteration of cells and and method to treat neoplasia TJ347B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/400,057 US6013626A (en) 1993-12-21 1995-03-07 Cryptophycins from synthesis
US08/482,141 US5952298A (en) 1993-12-21 1995-06-07 Cryptophycins
PCT/US1996/003246 WO1996040184A1 (en) 1995-03-07 1996-03-07 New cryptophycins from synthesis

Publications (1)

Publication Number Publication Date
TJ347B true TJ347B (en) 2002-10-06

Family

ID=27016884

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ97000493A TJ347B (en) 1995-03-07 1996-03-07 Cryptophicin compounds pharmacentical composition method to inhibit the proliteration of cells and and method to treat neoplasia

Country Status (22)

Country Link
EP (1) EP0830136B1 (ro)
JP (1) JP4181632B2 (ro)
CN (1) CN1165337C (ro)
AP (1) AP737A (ro)
AT (1) ATE279935T1 (ro)
AU (1) AU723652B2 (ro)
BG (1) BG63289B1 (ro)
CZ (1) CZ278197A3 (ro)
DE (1) DE69633667T2 (ro)
ES (1) ES2230561T3 (ro)
FI (1) FI973591A0 (ro)
GE (1) GEP20002206B (ro)
HU (1) HU225041B1 (ro)
MD (1) MD2196B2 (ro)
NO (1) NO326685B1 (ro)
NZ (1) NZ305571A (ro)
OA (1) OA10614A (ro)
PL (1) PL185949B1 (ro)
RO (1) RO118931B1 (ro)
SK (1) SK119997A3 (ro)
TJ (1) TJ347B (ro)
WO (1) WO1996040184A1 (ro)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008334A1 (en) * 1995-08-30 1997-03-06 University Of Hawaii Cryptophycins from aberrant biosynthesis
US5977387A (en) * 1996-08-30 1999-11-02 Eli Lilly And Company Process for preparing pharmaceutical compounds
IL128610A (en) * 1996-08-30 2004-07-25 Lilly Co Eli Cryptophycin compound and its use as a medicament for treating neoplasm
US6680311B1 (en) 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
KR20010029475A (ko) * 1996-09-06 2001-04-06 피터 지. 스트링거 약제학적 화합물의 제조 방법
CA2264245A1 (en) * 1996-09-06 1998-03-12 Eli Lilly And Company Process to prepare pharmaceutical compounds
CA2263764A1 (en) * 1996-09-06 1998-03-12 Michael John Martinelli Process and novel intermediates
AU738999B2 (en) * 1997-02-26 2001-10-04 Eli Lilly And Company Selective epoxidation process for preparing pharmaceutical compounds
CA2281107A1 (en) * 1997-02-26 1998-09-03 Eli Lilly And Company Tripeptide and tetrapeptide pharmaceutical compounds
EP0870501A1 (en) * 1997-04-11 1998-10-14 Eli Lilly And Company Use of specific cryptophycin derivatives for the manufacture of a medicament in the treatment of fungal infections
EP0870506A1 (en) * 1997-04-11 1998-10-14 Eli Lilly And Company Compositions comprising a cryptophycin compound in combination with a synchronizing or activating agent for treating cancer
EP0870510A3 (en) * 1997-04-11 1999-09-15 Eli Lilly And Company Synergistic combination comprising cryptophycin derivatives and microtubule synergizing agents
US6376230B1 (en) 1998-10-16 2002-04-23 Eli Lilly And Company Stereoselective process for producing intermediates of cryptophycins
US6103913A (en) * 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
IL142565A0 (en) * 1998-10-16 2002-03-10 Lilly Co Eli Stereoselective process for producing antineoplastic agents
AU1930100A (en) * 1998-12-07 2000-06-26 Eli Lilly And Company Crotylboration process to produce cryptophycin compounds
US6372936B1 (en) * 1999-06-09 2002-04-16 Eli Lilly And Company Optical resolution of aminoisobobutyric acid
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
CN114651000A (zh) * 2019-09-30 2022-06-21 密歇根大学董事会 念珠藻素抗癌剂的生物催化合成

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946835A (en) * 1988-07-15 1990-08-07 Merck & Co., Inc. Antifungal fermentation product and method
US4868208A (en) * 1988-07-15 1989-09-19 Merck & Co., Inc. Antifungal agent and method
US4845086A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
US4845085A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
CA2179490A1 (en) * 1993-12-21 1995-06-29 Trimurtulu Golakoti New cryptophycins

Also Published As

Publication number Publication date
MD970313A (ro) 1999-06-30
CN1165337C (zh) 2004-09-08
HU225041B1 (en) 2006-05-29
AU5360396A (en) 1996-12-30
AU723652B2 (en) 2000-08-31
PL185949B1 (pl) 2003-09-30
EP0830136A4 (en) 2001-01-24
BG101875A (en) 1998-10-30
DE69633667T2 (de) 2006-03-02
SK119997A3 (en) 1998-12-02
EP0830136A1 (en) 1998-03-25
CN1183726A (zh) 1998-06-03
OA10614A (en) 2001-03-15
WO1996040184A1 (en) 1996-12-19
HK1009747A1 (en) 1999-06-11
RO118931B1 (ro) 2004-01-30
FI973591A0 (fi) 1997-09-03
NZ305571A (en) 1999-02-25
BG63289B1 (bg) 2001-09-28
ES2230561T3 (es) 2005-05-01
NO326685B1 (no) 2009-01-26
DE69633667D1 (en) 2004-11-25
HUP9801880A2 (hu) 1998-11-30
PL322507A1 (en) 1998-02-02
NO974105D0 (no) 1997-09-05
HUP9801880A3 (en) 1999-08-30
NO974105L (no) 1997-11-05
CZ278197A3 (cs) 1998-12-16
AP737A (en) 1999-03-15
ATE279935T1 (de) 2004-11-15
JP4181632B2 (ja) 2008-11-19
EP0830136B1 (en) 2004-10-20
JPH11510476A (ja) 1999-09-14
GEP20002206B (en) 2000-08-25
MD2196B2 (ro) 2003-06-30
AP9701069A0 (en) 1997-10-30

Similar Documents

Publication Publication Date Title
TJ347B (en) Cryptophicin compounds pharmacentical composition method to inhibit the proliteration of cells and and method to treat neoplasia
PL322494A1 (en) Compounds and compositions intended to provide active substances
EP0871494A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR CELLS
AU2113295A (en) Novel compositions and methods for water treatment
AU5439996A (en) Compositions and methods for treating pain
ZA96740B (en) Skin treatment composition
GB9310241D0 (en) Cosmetic treatment of substrates
EP0874828A4 (en) PAIN TREATMENT COMPOSITIONS
GB9208921D0 (en) Electrochemical treatment of surfaces
EP0735894A4 (en) COMPOSITION AND METHODS FOR IMPROVING THE OUTCOME OF NERVOUS SYSTEM CONDITIONS
GB9601978D0 (en) Application of materials to substrates
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
AU7951591A (en) Methods for treating inflammation and compounds and compositions suitable for use therein
AU3477093A (en) 17beta -hydroxybenzoyl-4-aza-5alpha-androst-1-en-3-ones useful to treat baldness
GB9507297D0 (en) New composition of matter
AUPN380695A0 (en) Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions
IL124419A0 (en) Composition for treating pain
GB9510162D0 (en) Compositions for the treatment of skin conditions
AU7366591A (en) Method and composition for water treatment
LT95119A (en) Composition of whisky
AUPM836794A0 (en) Improved method and composition for the treatment of ulcers
ZA963825B (en) Composition of matter
HUP9903979A3 (en) Use of nitric oxidesynthase inhibitors to treat or prevent type ii diabetes
HU9402294D0 (en) Method and composition for reducing gasemission of dung water
PH30069A (en) Chlorothalonil composition and method of using the same as mulluscicide